A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors

Purpose The IGF-1R signaling pathway has been implicated in multiple cancers as important for cell survival, proliferation, invasion and metastasis. BIIB022 is a non-glycosylated human IgG4 monoclonal antibody (mAb) with specificity for IGF-1R. Unlike other anti-IGF1R antibodies, BIIB022 has no effe...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: von Mehren, Margaret, Britten, Carolyn D., Pieslor, Peter, Saville, Wayne, Vassos, Artemios, Harris, Sarah, Galluppi, Gerald R., Darif, Mohamed, Wainberg, Zev A., Cohen, Roger B., Leong, Stephen
Format: Artigo
Langue:Inglês
Publié: Springer US 2014
Sujets:
Phase I Studies
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4045341/
https://ncbi.nlm.nih.gov/pubmed/24458261
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0064-y
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires